Vane J R, Botting R M
William Harvey Research Institute, St Bartholomew's Hospital Medical College, London, UK.
Inflamm Res. 1995 Jan;44(1):1-10. doi: 10.1007/BF01630479.
The discovery of a second cyclooxygenase has provided fresh impetus to the search for new anti-inflammatory drugs. The second enzyme is effectively absent from healthy tissues but its levels rise dramatically during inflammation. It can be induced in migratory cells by bacterial lipopolysaccharide, cytokines and growth factors. The constitutive cyclooxygenase-1 (COX-1) can thus be considered a "housekeeping" enzyme, in contrast to cyclooxygenase-2 (COX-2) which is activated by tissue damage. Both enzymes have a molecular weight of around 70 kDa and similar Km and Vmax values for their reaction with arachidonic acid. Several non steroid anti-inflammatory drugs which have more than 1,000 fold selectivity for COX-2 over COX-1 are in the early stages of drug development.
第二种环氧化酶的发现为新型抗炎药物的研发提供了新的动力。在健康组织中实际上不存在这种第二种酶,但在炎症期间其水平会急剧上升。它可由细菌脂多糖、细胞因子和生长因子在游走细胞中诱导产生。因此,组成型环氧化酶 -1(COX -1)可被视为一种“管家”酶,与之形成对比的是,环氧化酶 -2(COX -2)是由组织损伤激活的。两种酶的分子量均约为70 kDa,并且它们与花生四烯酸反应的Km值和Vmax值相似。几种对COX -2的选择性比对COX -1高1000倍以上的非甾体抗炎药物正处于药物研发的早期阶段。